Heat shock proteins (HSPs) have been shown to act as adjuvants when coadministered with peptide antigens or given as fusion proteins and enhance the vaccination efficiency. To evaluate the enhancement of the potency of Hantaan virus (HTNV) nucleocapsid protein (NP) immunogenicity by heat shock protein 70 (HSP70), we developed a novel chimeric HTNV S-HSP70 DNA vaccine plasmid by genetically linking HSP70 gene to the full-length HTNV S segment DNA (HTNV S DNA). C57BL/6 mice were immunized with this plasmid followed by a subsequent boost with homologous recombinant protein. The levels of HTNV NP-specific antibody and cellular immune response were measured by use of ELISA, fluorescence activated cell sorter (FACS) analysis, cytotoxicity assay, and IFN-gamma ELISPOT assay. We found that HTNV S-HSP70 DNA vaccination significantly increased the levels of HTNV NP-specific antibody, IgG2a/IgG1 ratio, IFN-gamma producing CD8+ T-cell precursor frequencies, and cytotoxic T lymphocyte (CTL) response when compared with immunization with HTNV S DNA alone or HTNV S DNA physically mixed with HSP70 DNA. By contrast, HSP70 DNA or vector DNA immunization could not induce appreciable levels of specific antibodies and CTL response. Thus, we demonstrate for the first time that HSP70-based HTNV S DNA can induce both humoral and cellular immune response specific for HTNV NP and is a promising candidate DNA vaccine for HTNV infection.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vaccine.2006.07.040DOI Listing

Publication Analysis

Top Keywords

htnv dna
16
dna
13
dna vaccine
12
htnv
12
hsp70 gene
8
segment dna
8
nucleocapsid protein
8
heat shock
8
htnv s-hsp70
8
s-hsp70 dna
8

Similar Publications

Hantaan virus (HTNV) and Puumala virus (PUUV) are pathogenic zoonoses found in Asia and Europe, respectively. We conducted a randomized Phase 1 clinical trial of individual HTNV and PUUV DNA vaccines targeting the envelope glycoproteins (GnGc), as well as a combined HTNV/PUUV DNA vaccine delivered at varying doses using the PharmaJet Stratis® needle-free injection system (NCT02776761). Cohort 1 and 2 vaccines consisted of 2 mg/vaccination of HTNV or PUUV plasmid, respectively.

View Article and Find Full Text PDF
Article Synopsis
  • Hemorrhagic fever with renal syndrome (HFRS) is a serious illness in Eurasia with no specific treatments currently available, highlighting the need for safe and effective vaccines.
  • Researchers developed three types of nucleic acid vaccine candidates (mRNA, naked DNA, and DNA in lipid nanoparticles) targeting the Hantaan virus to assess their potential against HFRS.
  • All vaccine candidates successfully triggered strong immune responses similar to an existing inactivated vaccine, with the mRNA vaccine showing a robust T-helper 1 cell response and the DNA-LNP producing higher neutralizing antibodies, suggesting that combining these vaccines could enhance their effectiveness.
View Article and Find Full Text PDF
Article Synopsis
  • * SAB-163 is a new therapeutic treatment developed from transchromosomic bovine plasma, showing strong effectiveness against multiple hantavirus strains and extended bioavailability in animal models.
  • * The treatment has demonstrated protective effects in hamsters when administered around the time of exposure and is now ready for phase 1 clinical trials after passing safety and efficacy tests.
View Article and Find Full Text PDF

Vaccines has long been the focus of antiviral immunotherapy research. Viral epitopes are thought to be useful biomarkers for immunotherapy (both antibody-based and cellular). In this study, we designed a novel vaccine molecule, the Hantaan virus (HTNV) glycoprotein (GP) tandem Th epitope molecule (named the Gnc molecule), in silico.

View Article and Find Full Text PDF
Article Synopsis
  • Hantaan orthohantavirus (HTNV) causes hemorrhagic fever with renal syndrome (HFRS), leading to acute kidney injury and hemorrhaging; the role of neutrophils, the body's primary immune cells, in HFRS is still under investigation.
  • In this study, researchers measured plasma levels of myeloperoxidase (MPO) and MPO-DNA in HFRS patients, finding that plasma MPO levels significantly increased during the acute phase and in severe cases, while MPO-DNA levels remained unchanged.
  • Additionally, higher plasma MPO levels correlated with various inflammatory and kidney injury indicators, and neutrophil-platelet aggregates (NPAs) were found to be elevated in both acute
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!